Xylo Technologies Ltd. (XYLO)
- Previous Close
5.47 - Open
5.43 - Bid 5.55 x 100
- Ask 5.94 x 100
- Day's Range
5.23 - 5.64 - 52 Week Range
2.70 - 8.83 - Volume
4,473 - Avg. Volume
18,200 - Market Cap (intraday)
3.88M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-23.20 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 19, 2022
- 1y Target Est
--
Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops wireless vehicle battery charging technologies and modular electronic vehicles. The company was formerly known as Medigus Ltd. and changed its name to Xylo Technologies Ltd in April 2024. Xylo Technologies Ltd was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
www.medigus.comRecent News: XYLO
View More
Performance Overview: XYLO
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XYLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XYLO
View MoreValuation Measures
Market Cap
4.05M
Enterprise Value
1.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.07
Price/Book (mrq)
0.27
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.74%
Return on Assets (ttm)
-10.75%
Return on Equity (ttm)
-79.78%
Revenue (ttm)
57.64M
Net Income Avi to Common (ttm)
-15.99M
Diluted EPS (ttm)
-23.20
Balance Sheet and Cash Flow
Total Cash (mrq)
9.51M
Total Debt/Equity (mrq)
40.76%
Levered Free Cash Flow (ttm)
8.38M